Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.

Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, Hedderson M, Nessel L, Vaughn DJ, Strom BL, Ferrara A.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):636-45. doi: 10.1002/pds.3619. Epub 2014 Apr 25.

PMID:
24764283
2.

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL.

Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.

3.

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A.

JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.

PMID:
26197187
4.

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H.

Diabetologia. 2012 Jul;55(7):1953-62. doi: 10.1007/s00125-012-2538-9. Epub 2012 Mar 31.

5.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

6.

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.

Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH.

Diabet Med. 2013 Sep;30(9):1026-32. doi: 10.1111/dme.12144. Review.

PMID:
23350856
7.

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.

Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, Koshiyama H.

Diabetes Res Clin Pract. 2013 Feb;99(2):e21-3. doi: 10.1016/j.diabres.2012.11.013. Epub 2012 Dec 7.

PMID:
23228390
8.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

9.

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

Zhu Z, Shen Z, Lu Y, Zhong S, Xu C.

Diabetes Res Clin Pract. 2012 Oct;98(1):159-63. doi: 10.1016/j.diabres.2012.05.006. Epub 2012 Jun 16.

PMID:
22705039
10.

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group.; Diabetes and Cancer Research Consortium..

Diabetologia. 2015 Mar;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7.

PMID:
25481707
11.

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.

Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S.

BMJ. 2016 Aug 16;354:i3903. doi: 10.1136/bmj.i3903.

12.

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS.

Drug Saf. 2013 Aug;36(8):643-9.

PMID:
23797604
13.

Pioglitazone and bladder cancer: a propensity score matched cohort study.

Wei L, MacDonald TM, Mackenzie IS.

Br J Clin Pharmacol. 2013 Jan;75(1):254-9. doi: 10.1111/j.1365-2125.2012.04325.x.

14.

Observational follow-up of the PROactive study: a 6-year update.

Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A.

Diabetes Obes Metab. 2014 Jan;16(1):63-74. doi: 10.1111/dom.12180. Epub 2013 Aug 19.

PMID:
23859428
15.

Pioglitazone use and risk of bladder cancer: population based cohort study.

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L.

BMJ. 2016 Mar 30;352:i1541. doi: 10.1136/bmj.i1541.

16.

Pioglitazone use and the risk of bladder cancer.

Kuo HW, Tiao MM, Ho SC, Yang CY.

Kaohsiung J Med Sci. 2014 Feb;30(2):94-7. doi: 10.1016/j.kjms.2013.09.011. Epub 2013 Oct 29.

17.

Cohort study of pioglitazone and cancer incidence in patients with diabetes.

Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, Ehrlich SF, Habel LA.

Diabetes Care. 2011 Apr;34(4):923-9. doi: 10.2337/dc10-1067.

18.

Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.

Han E, Jang SY, Kim G, Lee YH, Choe EY, Nam CM, Kang ES.

Medicine (Baltimore). 2016 Feb;95(6):e2786. doi: 10.1097/MD.0000000000002786.

19.

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S.

BMJ. 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.

20.

Use of thiazolidinediones and risk of bladder cancer: disease or drugs?

Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML.

Curr Drug Saf. 2013 Nov;8(5):364-70.

PMID:
24215315

Supplemental Content

Support Center